Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian City, People's Republic of China.
Department of Cardiology, The First People's Hospital of Changde, Hunan province, People's Republic of China.
Hellenic J Cardiol. 2018 Sep-Oct;59(5):281-287. doi: 10.1016/j.hjc.2018.03.005. Epub 2018 Mar 30.
There are little data on the long-term clinical outcomes of optimal medical therapy (OMT) compared with successful percutaneous coronary intervention (PCI) in patients with chronic total occlusions (CTOs).
A total of 388 patients with ≥1 CTO were enrolled from January 2008 to December 2010. 62 patients were excluded, and 326 patients were divided into an OMT group (n = 125) and PCI group (n = 201) according to the initial treatment strategy. Propensity-score matching was also done to adjust for baseline characteristics. The primary outcome was major adverse cardiac event (MACE), included cardiac death, recurrent myocardial infarction, and repeated revascularization.
After a mean follow-up of 47.2 ± 20.0 months, there was no significant difference between the two groups with respect to the prevalence of MACE (successful PCI vs. OMT: 29.6% vs. 21.9%, unadjusted hazard ratio [HR] 1.47, 95% confidence interval [CI] 0.95-2.28, p=0.085). After multivariate analyses, there were significant differences in the prevalence of MACE (adjusted HR 1.76, 95% CI 1.09-2.28, p=0.02) and repeated revascularization (2.14; 1.18-3.90, 0.01). In the propensity score-matched population (80 pairs), there were no significant differences in the prevalence of MACE (adjusted HR 1.89, 95% CI 0.96-3.71, p=0.06) and cardiac death (1.30, 0.44-3.80, 0.63) between groups.
In the treatment of patients with CTOs, successful PCI did not reduce the long-term risk of MACE compared with OMT.
对于慢性完全闭塞(CTO)患者,与经皮冠状动脉介入治疗(PCI)相比,优化药物治疗(OMT)的长期临床结局数据较少。
2008 年 1 月至 2010 年 12 月,共纳入 388 例至少有 1 例 CTO 的患者。排除 62 例患者,根据初始治疗策略将 326 例患者分为 OMT 组(n=125)和 PCI 组(n=201)。还进行了倾向评分匹配以调整基线特征。主要终点是主要不良心脏事件(MACE),包括心脏死亡、再发心肌梗死和再次血运重建。
平均随访 47.2±20.0 个月后,两组 MACE 发生率(成功 PCI 与 OMT:29.6%与 21.9%,未调整的风险比[HR]1.47,95%置信区间[CI]0.95-2.28,p=0.085)无显著差异。多变量分析后,MACE 发生率(调整 HR 1.76,95%CI 1.09-2.28,p=0.02)和再次血运重建(2.14;1.18-3.90,0.01)有显著差异。在倾向评分匹配人群(80 对)中,MACE 发生率(调整 HR 1.89,95%CI 0.96-3.71,p=0.06)和心脏死亡(1.30,0.44-3.80,p=0.63)无显著差异。
在 CTO 患者的治疗中,与 OMT 相比,成功 PCI 并不能降低长期 MACE 的风险。